ABCL News and Press, AbCellera Biologics Inc. From 02/20/24

2024-02-20 23:45:21 ET AbCellera Biologics Inc. (ABCL) Q4 2023 Results Conference Call February 20, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Part...

2024-02-20 23:00:16 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q4 2023 Earnings Call Feb 20, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q4 2023 Earnings Call Tran...

2024-02-20 16:11:18 ET More on AbCellera Biologics AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Abs...

Total revenue of $38 million, compared to $485 million in FY 2022 Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year Net loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (dil...

Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...

2024-02-19 17:35:09 ET Major earnings expected after the bell on Tuesday include: Realty Income Corporation ( O ) Teladoc Health ( TDOC ) Palo Alto Networks ( PANW ) Chesapeake Energy Corporation ( CHK ) SolarEdge Technologies ( SEDG ) Read ...

2024-02-16 17:20:10 ET More on AbCellera Biologics AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Abs...

2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...

AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link tha...

2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...